- Company
- Xofluza efficacy confirmed in household transmission
- by Eo, Yun-Ho Jul 14, 2020 06:12am
- A next-generation flu drug Xofluxa’s effect of preventing flu virus transmission among the patient’s household member has been confirmed. The latest edition of New England Journal of Medicine (NEJM) published on July 8 reported the clinical findings of Xofluza (baloxavir marboxil) and its flu preventive effect. The study evaluated
- InterView
- AlphaGo will lead the development of new drugs
- by Nho, Byung Chul Jul 14, 2020 06:12am
- "The future vision of the Center for AI-based New Drug Development Facilitation is the development of a global first in class drug that combines artificial intelligence and medical data." For Hwa Jong Kim (62 years old, director), the direction of organizational management of the Center for AI-based New Drug Development Facilitation is to
- Policy
- Nine out of 27 patients in Remdesivir improved
- by Kim, Jung-Ju Jul 14, 2020 06:12am
- Of the 27 COVID-19 patients in Korea who took Remdesivir, 9 cases improved out of 27 patients with severe change. The positive effect was about 30%, which is only a numerical example and is still under professional review. Deputy General Manager Kwon Joon-Wook, the Central Disease Control Headquarters of the KCDC (Director, Eun-kyeong J
- Company
- 14 new drugs approved from Jan to June with no Korean drug
- by Jul 14, 2020 06:12am
- Korea’s Ministry of Food and Drug Safety (MFDS) reported total 14 new drugs have been approved from Jan 1 to June 30 this year. While none of them were a Korean-made, the absence of Korean-made new drug has continued for two years now. Pfizer Pharmaceutical Korea, Astellas Pharma Korea and Bayer Korea received the highest number of new drug
- Policy
- Forxiga's pro-drug by Dong-A ST, conducted clinical trials
- by Lee, Tak-Sun Jul 14, 2020 06:11am
- Dong-A ST recently succeeded in overcoming a material patent, and SGLT-2 suppression-based diabetes treatment Forxiga by AstraZeneca is speeding up commercialization. IND has already been approved by the MFDS in April. According to the MFDS on the 10th, IND of Dong-A ST's 'DA-2811' was approved on April 16 to confirm its equivalence with
- Company
- LG Chem launches filler's clinical trial in China
- by An, Kyung-Jin Jul 14, 2020 02:34am
- LG Chem is launching a large-scale clinical trial in China with the new product of Yvoire, a hyaluronic acid filler brand. It is an ambition to secure the differentiation and expand the market share by preparing clinical data of Y-Solution, which was introduced as a premium line. LG Chem recently unveiled a new clinical trial plan for Yvo
- Company
- DongKook & YuYu have challenged Dutasteride &Tadalafil
- by Kim, Jin-Gu Jul 13, 2020 06:13am
- The prostate hyperplasia & erectile dysfunction complex market competition is expected to become even hotter. With only Hanmi's Gugu tams (Tamsulosin + Tadalafil ) released on the market, DongKook and YuYu Pharma have challenged. According to the pharmaceutical industry on the 13th, DongKook recently approved a clinical trial phase III IN
- Company
- Eligibility for HPV vaccine Gardasil9 extends up to age 45 i
- by Eo, Yun-Ho Jul 13, 2020 06:12am
- Vaccination eligible age for the human papillomavirus (HPV) vaccine Gardasil9 has been extended up to age 45 in Korea. Pharmaceutical industry sources reported Ministry of Food and Drug Safety (MFDS) has approved MSD expanding the indication to vaccinate in female aged 27 to 45. Unlike the U.S., however, the Korean health authority exclud
- Policy
- NHIS expects avg 322 generic pricing negotiations per month
- by Lee, Hye-Kyung Jul 13, 2020 06:12am
- Korea’s National Health Insurance Service (NHIS) is to start negotiating with generics over healthcare reimbursement contracts from the second half of the year. At a press conference convened on July 7, NHIS Reimbursement Executive Director Kang Chung-hee stated, “For the pricing negotiation on generics to be conducted from August to S
- Policy
- Clarifying the conditional approval target
- by Lee, Tak-Sun Jul 13, 2020 06:12am
- The MFDS strictly enforces the Advanced Bio Act (the Act on the “Safety and Support of Advanced Regenerative Medical and Advanced Biopharmaceuticals”), and said that concerns about safety are only a concern. However, the conditional approvals subject to the enacted legislation will maintain the previous conditions. Ho-sang Jeong, chie
